AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19289172 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 27
Study 17227904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (50 mg b.i.d. for 21 days), thalidomide (200 mg/day), and prednisone (50 mg q.o.d.)
Number of subjects: 37
Study 17227904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide, thalidomide, and prednisone (CTP)
Number of subjects: 37
Study 15954068 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 18
Study 15954068 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 18
Study 15954068 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 18
Study 11893836 — intervention group
Group type: EXPERIMENTAL
Intervention: TELE
Number of subjects: 56
Study 11893836 — intervention group
Group type: EXPERIMENTAL
Intervention: TICS
Number of subjects: 56
Study 9468751 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group asked to reduce salivation
Number of subjects: 3
Study 9468751 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group asked to reduce salivation and promised a reward if successful
Number of subjects: 3
Study 9468751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 7657279 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion
Number of subjects: 18
Study 7657279 — intervention group
Group type: COMPARATOR
Intervention: No albumin infusion (Control)
Number of subjects: 18
Study 2663695 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon-2a, 9 million units intramuscularly three times weekly for 16 weeks, followed by 3 million units three times weekly for an additional 8 weeks if viremic after 16 weeks.
Number of subjects: 30
Study 2663695 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (12 patients).
Number of subjects: 30
Study 2663695 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon-2a (treated group).
Number of subjects: 30
Study 1151628 — intervention group
Group type: EXPERIMENTAL
Intervention: Elixir, 0.5 mg digoxin
Number of subjects: 16
Study 1151628 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid dissolution tablet, 0.5 mg digoxin
Number of subjects: 16
Study 1151628 — intervention group
Group type: COMPARATOR
Intervention: Slow dissolution tablet, 0.5 mg digoxin
Number of subjects: 16
Study 1151628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration, 0.5 mg digoxin
Number of subjects: 16
Study 29554013 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-NMES (60 Hz)
Number of subjects: 11
Study 29554013 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-NMES (20 Hz)
Number of subjects: 11
Study 28774317 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-led care
Number of subjects: 70
Study 28774317 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual cardiologist consultation)
Number of subjects: 70
Study 26437761 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium nitrate (NO donor)
Number of subjects: 19
Study 26437761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24521888 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone-based quadruple therapy (Esomeprazole 20 mg twice daily, furazolidone 100 mg twice daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days)
Number of subjects: 156
Study 24521888 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin-based quadruple therapy (Esomeprazole 20 mg twice daily, levofloxacin 500 mg daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days)
Number of subjects: 156
Study 21248158 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of HPV vaccine (Gardasil) for group 1, months 0 and 6
Number of subjects: 824
Study 21248158 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of HPV vaccine (Gardasil) for group 2, months 0, 2, and 6
Number of subjects: 824
Study 21248158 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of HPV vaccine (Gardasil) for group 3, months 0, 2, and 6
Number of subjects: 824
Study 18081355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 400 microg buccally
Number of subjects: 90
Study 18081355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 400 microg sublingually
Number of subjects: 90
Study 16448525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 or 15 mg continuously for 12 months
Number of subjects: 928
Study 14567773 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene HCl 60 mg daily
Number of subjects: 187
Study 14567773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 11375775 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) delivered intermittently at low doses
Number of subjects: 0
Study 11375775 — intervention group
Group type: EXPERIMENTAL
Intervention: New PTH analogues
Number of subjects: 0
Study 9758073 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychological treatment program (self-help techniques, cognitive behavioral strategies, relaxation, physical exercises)
Number of subjects: 27
Study 9758073 — intervention group
Group type: COMPARATOR
Intervention: Control group (autogenic training)
Number of subjects: 27
Study 9758073 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychological treatment program
Number of subjects: 27
Study 8076546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxygen supplementation
Number of subjects: 79
Study 8076546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapharyngeal oxygen supplementation
Number of subjects: 79
Study 8076546 — intervention group
Group type: COMPARATOR
Intervention: No supplementary oxygen (lower-risk group)
Number of subjects: 79
Study 8076546 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary oxygen (lower-risk group)
Number of subjects: 79
Study 3396490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 2g intravenously
Number of subjects: 27
Study 3396490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2g intravenously
Number of subjects: 27
Study 3396490 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (controls)
Number of subjects: 27
Study 31538282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (REVATIO®)
Number of subjects: 0
Study 31538282 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial simulations
Number of subjects: 0
Study 28741805 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular noninvasive magnetic acupuncture (MA)
Number of subjects: 40
Study 28741805 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40
Study 26548726 — intervention group
Group type: EXPERIMENTAL
Intervention: AverTeaX applied topically six to eight times daily
Number of subjects: 40
Study 26548726 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (100% glycerin USP)
Number of subjects: 40
Study 22976217 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (1.25 g BID)
Number of subjects: 12
Study 22065532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg daily)
Number of subjects: 60
Study 22065532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19636326 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17013640 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming drink (0.03 g/dl alcohol)
Number of subjects: 16
Study 17013640 — intervention group
Group type: COMPARATOR
Intervention: Taste-masked placebo
Number of subjects: 16
Study 14760122 — intervention group
Group type: EXPERIMENTAL
Intervention: COPP/ABV/IMEP (CAI)
Number of subjects: 588
Study 14760122 — intervention group
Group type: COMPARATOR
Intervention: COPP/ABVD (CA)
Number of subjects: 588
Study 11258039 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion-olive oil maceration product (4 capsules daily)
Number of subjects: 24
Study 11258039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 capsules daily)
Number of subjects: 24
Study 9290856 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative outcome task
Number of subjects: 55
Study 9290856 — intervention group
Group type: COMPARATOR
Intervention: Neutral outcome control task
Number of subjects: 55
Study 9290856 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating (after negative outcome task)
Number of subjects: 55
Study 29266863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline (3% HS) with 2.5 mg salbutamol
Number of subjects: 47
Study 29266863 — intervention group
Group type: COMPARATOR
Intervention: Nebulized normal saline (NS) with 2.5 mg salbutamol
Number of subjects: 47
Study 27439433 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2 g (1 g twice daily) plus lifestyle
Number of subjects: 60
Study 27439433 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle alone
Number of subjects: 60
Study 24760745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic pole walking (NPW+)
Number of subjects: 52
Study 24760745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic pole walking (NPW-)
Number of subjects: 52
Study 24760745 — intervention group
Group type: COMPARATOR
Intervention: Standard home exercise programme (HEP)
Number of subjects: 52
Study 22427815 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM1 model integrating the expression of 7 molecular biomarkers
Number of subjects: 97
Study 22427815 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM2 model grouping the expression level of 12 molecular biomarkers and 3 EBV‐related serological biomarkers
Number of subjects: 97
Study 22427815 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM3 model constructed by combination of SVM1 and SVM2
Number of subjects: 97
Study 22427815 — intervention group
Group type: COMPARATOR
Intervention: Cox multivariate regression analysis
Number of subjects: 97
Study 19625372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention targeting LDL-cholesterol <100 mg/dl, using antiplatelet therapy, and switching protease inhibitor therapy.
Number of subjects: 68
Study 19625372 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention aiming for LDL-cholesterol <130 mg/dL.
Number of subjects: 68
Study 16413333 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostat/Poltit
Number of subjects: 60
Study 16413333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14993579 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (0.1 to 0.2 mL subcutaneously injected just before PIV insertion)
Number of subjects: 69
Study 14993579 — intervention group
Group type: COMPARATOR
Intervention: ELA-Max (applied to the skin and occluded with Tegaderm 30 minutes before PIV insertion)
Number of subjects: 69
Study 14993579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse ratings of technical difficulty and satisfaction with local anesthesia
Number of subjects: 69
Study 14993579 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of PIV-insertion attempts
Number of subjects: 69
Study 11237931 — intervention group
Group type: EXPERIMENTAL
Intervention: HFLC diet
Number of subjects: 6
Study 11237931 — intervention group
Group type: COMPARATOR
Intervention: LFHC diet
Number of subjects: 6
Study 9786562 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma (NTG) eyes
Number of subjects: 27
Study 9786562 — intervention group
Group type: COMPARATOR
Intervention: Normal eyes (control)
Number of subjects: 27
Study 7837398 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg orally
Number of subjects: 90
Study 7837398 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg orally
Number of subjects: 90
Study 7837398 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intramuscularly
Number of subjects: 90
Study 7837398 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (all groups)
Number of subjects: 90
Study 3349552 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackson-Rees system (n = 11)
Number of subjects: 26
Study 3349552 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric circle absorber system (n = 15)
Number of subjects: 26
Study 3349552 — intervention group
Group type: COMPARATOR
Intervention: Jackson-Rees system
Number of subjects: 26
Study 3349552 — intervention group
Group type: COMPARATOR
Intervention: Paediatric circle absorber system
Number of subjects: 26
Study 31769331 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilting group (standing on a tilting board)
Number of subjects: 20
Study 31769331 — intervention group
Group type: COMPARATOR
Intervention: Control group (voluntarily leaning forward)
Number of subjects: 20
Study 31504831 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction
Number of subjects: 60
Study 31504831 — intervention group
Group type: COMPARATOR
Intervention: Written handout
Number of subjects: 60
Study 31260166 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpositional block graft
Number of subjects: 20
Study 31260166 — intervention group
Group type: COMPARATOR
Intervention: Onlay graft
Number of subjects: 20
Study 28470507 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12-week post-radiation)
Number of subjects: 59
Study 28470507 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 59
Study 26179223 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative self‐perceived risk of addiction
Number of subjects: 107
Study 26179223 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety sensitivity
Number of subjects: 107
Study 23611404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel
Number of subjects: 1139
Study 23611404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-gemcitabine
Number of subjects: 1139
Study 23611404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-docetaxel
Number of subjects: 1139
Study 23611404 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel
Number of subjects: 1139
Study 23611404 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology subtypes (SCC, AC, LCC, O/NOS)
Number of subjects: 1139
Study 21321633 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing toothpaste containing 5.53% potassium citrate
Number of subjects: 67
Study 21321633 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste containing 0.76% sodium monofluorophosphate
Number of subjects: 67
Study 18505216 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-Start (SS) technique
Number of subjects: 20
Study 18505216 — intervention group
Group type: COMPARATOR
Intervention: Plasma Arc Curing (PAC) technique
Number of subjects: 20
Study 17191188 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis)
Number of subjects: 0
Study 17191188 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PDT and intravitreal triamcinolone acetonide
Number of subjects: 0
Study 17191188 — intervention group
Group type: COMPARATOR
Intervention: PDT with verteporfin
Number of subjects: 0
Study 14687246 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid surgery
Number of subjects: 3213
Study 14687246 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 3213
Study 11398072 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg of IL‐4R
Number of subjects: 62
Study 11398072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 9258715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture supported by two implants with ball attachments
Number of subjects: 110
Study 9258715 — intervention group
Group type: EXPERIMENTAL
Intervention: Two implants with an interconnecting bar
Number of subjects: 110
Study 9258715 — intervention group
Group type: EXPERIMENTAL
Intervention: Four interconnected implants
Number of subjects: 110
Study 8278211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain events
Number of subjects: 0
Study 8278211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain event memory
Number of subjects: 0
Study 8278211 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress
Number of subjects: 0
Study 8278211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity and sensory quality of pain
Number of subjects: 0
Study 3434167 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 2
Study 3434167 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 2
Study 3434167 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 2
Study 30913381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon-flocked (NF) swab cytology
Number of subjects: 326
Study 30913381 — intervention group
Group type: COMPARATOR
Intervention: Dacron swab cytology
Number of subjects: 326
Study 28612375 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE chemotherapy and 25.5 Gy of involved field radiotherapy for low-risk HL (P9426)
Number of subjects: 471
Study 28612375 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE-PC chemotherapy and 21 Gy of involved region radiotherapy for intermediate and high-risk HL (P9425)
Number of subjects: 471
Study 28612375 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EFS between children and AYA
Number of subjects: 471
Study 25434365 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg) administered 30 min prior to surgery and every 12 h for 60 h
Number of subjects: 80
Study 25434365 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group) administered at corresponding time points
Number of subjects: 80
Study 23835245 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day
Number of subjects: 702
Study 23835245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study 21592110 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (Exjade), average dose 19.4 ± 6.3 mg/kg per day
Number of subjects: 185
Study 21592110 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (Exjade)
Number of subjects: 185
Study 19116326 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher α-tocopherol concentrations (highest compared with lowest quintile)
Number of subjects: 29092
Study 19116326 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat intake (>9.9 g/d) with higher α-tocopherol concentrations
Number of subjects: 29092
Study 19116326 — intervention group
Group type: COMPARATOR
Intervention: Dietary tocopherols and tocotrienols
Number of subjects: 29092
Study 16713013 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, etoposide, and carboplatin (TEC) regimen
Number of subjects: 614
Study 16713013 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin, etoposide phosphate, and vincristine (CEV) regimen
Number of subjects: 614
Study 14717835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mimicry
Number of subjects: 0
Study 14717835 — intervention group
Group type: COMPARATOR
Intervention: Non-mimicry (Control)
Number of subjects: 0
Study 11696142 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 55
Study 11696142 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 55
Study 9246969 — intervention group
Group type: EXPERIMENTAL
Intervention: fosfomycin
Number of subjects: 11
Study 9246969 — intervention group
Group type: COMPARATOR
Intervention: CAPF chemotherapy alone (control)
Number of subjects: 11
Study 7970444 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm‐N,N'‐ethylene‐1‐dicysteine (99Tcm‐EC) complex
Number of subjects: 0
Study 3296254 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef sodium
Number of subjects: 40
Study 3296254 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 40
Study 31704159 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation strategies for preventive cardiovascular care
Number of subjects: 107
Study 31704159 — intervention group
Group type: COMPARATOR
Intervention: EHRs that were unable to consistently produce rolling 12-month measures
Number of subjects: 107
Study 30823460 — intervention group
Group type: EXPERIMENTAL
Intervention: FRED Exergame with biofeedback supervision
Number of subjects: 40
Study 30823460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 30823460 — intervention group
Group type: EXPERIMENTAL
Intervention: FRED Exergame
Number of subjects: 40
Study 29258541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron polymaltose (single dose calculated using the Ganzoni formula)
Number of subjects: 100
Study 29258541 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusion
Number of subjects: 100
Study 25683075 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based treatment programme (n = 124)
Number of subjects: 250
Study 25683075 — intervention group
Group type: COMPARATOR
Intervention: Postal treatment programme (n = 126)
Number of subjects: 250
Study 26265274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 900
Study 26265274 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 900
Study 21560159 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 2388
Study 21560159 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 2388
Study 21560159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2388
Study 19778672 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819
Study 19778672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819
Study 19778672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 13819
Study 17691578 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation (Acup+ Rehab)
Number of subjects: 56
Study 17691578 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (Rehab)
Number of subjects: 56
Study 17691578 — intervention group
Group type: COMPARATOR
Intervention: Control (medication, manicol/beronald, Ca2+ antagonist, citicoline, etc.)
Number of subjects: 56